Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer

2011619 citationsJournal Articlegreen Open Access

Authors

Da Yang · The University of Texas MD Anderson Cancer Center

Sofia Khan · University of Helsinki

Yan Sun · The University of Texas MD Anderson Cancer Center

Kenneth R. Hess · The University of Texas MD Anderson Cancer Center

Ilya Shmulevich · InSysBio (Russia)

Anil K. Sood

Wei Zhang · University of Helsinki

Abstract

Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type.

Topics & Keywords

BRCA gene mutations in cancer Ovarian cancer diagnosis and treatment DNA Repair Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 306, Issue 14, pp. 1557-1557

DOI: 10.1001/jama.2011.1456

Field-Weighted Citation Impact: 26.40